2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1603 Association of GLP-1 receptor agonist with survival, relapse, and remission in acute leukemia: A target trial emulation study

Dominic Earl Mitchell Jarrett, MD, Omar Farooq Amir, MD2, Travis Edward Stueber, DO3, Anum Jalil4, Ahmed Bashir Sukhera, MD5, Prashanth Kotla, MD6, Yajur Arya, MD7, Arshi Syal, MD8, Colton Jones, MD, Hematology, Oncologyfellow9, Anand Karnad, MD10
1 University of Miami, Miami, Florida, United States
2 UT Health San Antonio, San Antonio, Texas, United States
3 UT Health San Antonio, San Antonio, Texas, United States
4 UT Health San Antonio, San Antonio, Texas, United States
5 UT Health San Antonio, San Antonio, Texas, United States
6 UT Health San Antonio, San Antonio, Texas, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 Mayo Clinic, Jacksonville, Florida, United States
9 UT Health San Antonio, San Antonio, Texas, United States
10 UT Health San Antonio, San Antonio, Texas, United States

Background:

GLP-1 receptor agonists (GLP1-RAs), initially developed for metabolic disease, demonstrate immunomodulatory and anti-proliferative properties in preclinical models. Retrospective studies reported reduced hematologic malignancy incidence among diabetics receiving GLP1-RAs; however, their impact on outcomes in acute leukemia remains unknown. This study is the first target trial emulation framework to evaluate the association of GLP1-RA exposure after diagnosis with overall survival (OS), remission, and relapse in acute myeloid leukemia (AML) and  (ALL).

 Methods We conducted a retrospective target trial emulation using the TriNetX Global Collaborative Network. Adults (≥18 years) with new AML or ALL between January 2015–December 2024 were eligible. Exclusions: prior GLP1-RA exposure, second hematologic malignancy, or <6 months follow-up. Treatment was initiation of any GLP1-RA within 6 months; comparator had none. Time zero was leukemia diagnosis, with a 6-month landmark. The primary endpoint was OS; secondary endpoints were remission and relapse. Cohorts were 1:1 propensity score matched on demographics, BMI, HbA1c, comorbidities, chemotherapy, and stem cell transplantation. Multivariable logistic regression estimated odds ratios (ORs) with 95% confidence intervals (CIs).

 Results After matching, 5,710 patients were analyzed (n=2,855 per cohort). The GLP1-RA cohort median age was 54 (56% female; 70% White, 14% Black, 12% Hispanic; BMI 34; HbA1c 6.5%); control median age was 59 (55% female; 71% White, 15% Black, 11% Hispanic; BMI 28; HbA1c 5.8%). At a median follow-up of 860 days, GLP1-RA exposure improved OS (OR 0.21; 95% CI 0.18–0.26; p<0.001). This benefit was consistent across obese (OR 0.23; 95% CI 0.18–0.30; p<0.001), non-obese (OR 0.25; 95% CI 0.18–0.33; p<0.001), diabetic (OR 0.28; 95% CI 0.21–0.36; p<0.001), non-diabetic (OR 0.19; 95% CI 0.13–0.26; p<0.001), and semaglutide-exposed (OR 0.17; 95% CI 0.12–0.24; p<0.001). Tirzepatide subgroup was underpowered.

 In AML, GLP1-RA exposure improved remission rates (OR 1.31; 95% CI 1.09–1.58; p=0.004), which were significant in obese (OR 1.29; 95% CI 1.01–1.64; p=0.04) and semaglutide-exposed (OR 1.50; 95% CI 1.09–2.05; p=0.01). No benefit was observed in non-obese, diabetic, non-diabetic, or tirzepatide subgroups. Relapse was reduced (OR 0.57; 95% CI 0.47–0.69; p<0.001), consistent across obese (OR 0.73; 95% CI 0.56–0.94; p=0.02), non-obese (OR 0.60; 95% CI 0.43–0.84; p=0.003), diabetic (OR 0.57; 95% CI 0.42–0.78; p<0.001), non-diabetic (OR 0.58; 95% CI 0.42–0.79; p<0.001), semaglutide-exposed (OR 1.50; 95% CI 1.09–2.05; p=0.01), and tirzepatide-exposed subgroups (OR 0.53; 95% CI 0.30–0.95; p=0.03).

 In ALL, GLP1-RA exposure was not significantly associated with remission (OR 1.20; 95% CI 0.97–1.48; p=0.10) or relapse (OR 1.25; 95% CI 0.93–1.69; p=0.14). Subgroup analysis showed improved remission in non-obese (OR 1.53; 95% CI 1.03–2.25; p=0.03) and tirzepatide-exposed (OR 2.02; 95% CI 1.08–3.76; p=0.02) subgroups. Reduced relapse was observed in diabetic (OR 0.63; 95% CI 0.40–0.99; p=0.04) and non-diabetic patients (OR 0.67; 95% CI 0.46–0.99; p=0.04), but not in obese, non-obese, semaglutide, or tirzepatide subgroups.

 Conclusions

GLP1-RA exposure after acute leukemia diagnosis was associated with a 79% reduction in mortality, consistent across BMI, glycemic status, and agent. AML patients showed significant improvements in remission and relapse, while ALL patients had subgroup-specific benefits. Consistency in non-obese and non-diabetic patients suggests immunomodulatory effects independent of metabolic pathways. Limitations include residual confounding and absence of cytogenetic, molecular, and treatment-specific data. These findings, representing the largest analysis of GLP1-RA exposure in acute leukemia to date, warrant prospective validation in randomized trials.

Dominic Earl Mitchell Jarrett, MD: No relevant conflicts of interest to declare.